Compare Goldman Sachs Group Inc (GS) vs Teladoc Health Inc (TDOC) Price & Performance

Goldman Sachs (GS) trades at $887.21, down 1.11% on the day, with a bearish technical signal despite strong fundamental performance. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $20.98 significantly exceeding expectations of $14.47. Revenue growth accelerated to $58.28 billion in 2025, while net income margin improved to 29.46%. Analyst consensus remains positive with a $1,130 price target, though technical indicators show selling pressure.

GS presents a compelling value opportunity with a P/E of 13.63 below industry averages, supported by robust earnings growth and a 31.68% net income margin. However, negative operating cash flow of -$45.15 billion in 2025 and bearish technical momentum create near-term headwinds. The stock's 18.33% ROE and dividend yield of approximately 0.56% provide shareholder returns, but investors should monitor cash flow trends and FICC business performance highlighted in recent management commentary.

Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.

The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.